Compare MPWR & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPWR | BDX |
|---|---|---|
| Founded | 1997 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 51.5B |
| IPO Year | 2004 | 1995 |
| Metric | MPWR | BDX |
|---|---|---|
| Price | $1,175.77 | $154.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $1,122.93 | $188.73 |
| AVG Volume (30 Days) | 443.9K | ★ 2.1M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | 0.72% | ★ 2.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.86 | 1.34 |
| Revenue | $333,067,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $23.74 | N/A |
| Revenue Next Year | $17.55 | $2.22 |
| P/E Ratio | ★ $86.97 | $115.31 |
| Revenue Growth | ★ 17.89 | 8.24 |
| 52 Week Low | $438.86 | $153.18 |
| 52 Week High | $1,256.22 | $213.08 |
| Indicator | MPWR | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 33.12 |
| Support Level | $899.99 | $153.75 |
| Resistance Level | $1,253.11 | $160.19 |
| Average True Range (ATR) | 48.32 | 3.31 |
| MACD | 10.99 | 0.92 |
| Stochastic Oscillator | 97.23 | 20.37 |
Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.